p62 upregulation is observed in most human CLDs that predispose to HCC progression [68], but whether there is a certain threshold or additional molecular requirements for p62 to elicit strong NRF2 activation is unclear. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.